Test Code CHFXH Chromosome Analysis, Hematologic Disorders, Fixed Cells
Reporting Name
Chromosomes, Hematol Fixed CellsPerforming Laboratory
Mayo Clinic Laboratories in RochesterUseful For
Assisting in the diagnosis and classification of certain malignant hematological disorders in fixed cells
Evaluating the prognosis of patients with certain malignant hematologic disorders
Monitoring effects of treatment
Monitoring patients in remission
Method Name
Chromosome Analysis
Necessary Information
A pathology and/or flow cytometry report may be requested by the Genomics Laboratory to optimize testing and aid in interpretation of results.
Provide a reason for testing and specimen type with each specimen. The laboratory will not reject testing if this information is not provided, but appropriate testing and interpretation may be compromised or delayed.
Specimen Required
Specimen Volume: 2 mL
Additional Information: Advise Express Mail or equivalent if not on courier service.
Specimen Type
VariesSpecimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Ambient (preferred) | ||
Refrigerated |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Reference Values
An interpretative report will be provided.
Interpretation
To ensure the best interpretation, it is important to provide some clinical information to verify the appropriate type of cytogenetic study is performed.
The following factors are important when interpreting the results:
-Although the presence of an abnormal clone usually indicates a malignant neoplastic process, in rare situations, the clone may reflect a benign condition.
-The absence of an abnormal clone may be the result of specimen collection from a site that is not involved in the neoplasm or may indicate that the disorder is caused by submicroscopic abnormalities that cannot be identified by chromosome analysis.
-On rare occasions, the presence of an abnormality may be associated with a congenital abnormality that is not related to a malignant neoplastic process. Follow-up with a medical genetics consultation is recommended.
-On occasion, bone marrow chromosome studies are unsuccessful. If clinical information has been provided, we may have a FISH study option that could be performed.
Day(s) Performed
Monday through Friday
Report Available
10 to 11 daysTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
88291- Interpretation and report
88264 w/ modifier 52-Chromosome analysis with less than 20 cells (if appropriate)
88264-Chromosome analysis with 20 to 25 cells (if appropriate)
88264, 88285-Chromosome analysis with greater than 25 cells (if appropriate)
88283-Additional specialized banding technique (if appropriate)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
CHFXH | Chromosomes, Hematol Fixed Cells | In Process |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
38487 | Result Summary | 50397-9 |
38488 | Interpretation | 69965-2 |
38489 | Result | 62356-1 |
38490 | Reason for Referral | 42349-1 |
38491 | Specimen | 31208-2 |
38492 | Source | 31208-2 |
38493 | Method | 85069-3 |
38494 | Banding Method | 62359-5 |
38495 | Additional Information | 48767-8 |
38496 | Released By | 18771-6 |
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
_ML20 | Metaphases, 1-19 | No, (Bill Only) | No |
_M25 | Metaphases, 20-25 | No, (Bill Only) | No |
_MG25 | Metaphases, >25 | No, (Bill Only) | No |
_STAC | Ag-Nor/CBL Stain | No, (Bill Only) | No |
Testing Algorithm
This test only includes a charge for professional interpretation of results and does not include charges for analysis.
Analysis charges will be incurred for total work performed, and generally include 2 banded karyograms and the analysis of 20 or more metaphase cells for this test. If no metaphase cells are available for analysis, no analysis charges will be incurred. If additional analysis work is required, additional charges may be incurred. See the Method Description for specific details.
For more information see:
-Acute Promyelocytic Leukemia: Guideline to Diagnosis and Follow-up
-Bone Marrow Staging for Known or Suspected Malignant Lymphoma Algorithm
-Multiple Myeloma: Laboratory Screening
-Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation